Regression
Regression in Adolescents and Adults with Down Syndrome
October 2018 | Chicoine & Capone - Chapter in Physical Health of Adults with Intellectual and Developmental Disabilities
Abstract:
There has been a growing number of clinical case reports of regression in adolescents and adults with Down syndrome who have shown unexpected and severe regression in cognitive and adaptive functioning, motor function, communication skills, and behavior. In this chapter, we call this adult regression syndrome. It most commonly affects people with Down syndrome in their teens and twenties and is associated with cognitive-executive impairment, social withdrawal, loss of functional language and previously acquired adaptive skills, lasting greater than 3 months. The differential diagnosis is extensive suggesting that the brains of individuals with Down syndrome are vulnerable to further impairment from a variety of underlying causes. Several of the most important diagnoses are discussed further. Prognosis is highly dependent on both the cause and the certainty of the diagnosis. Further study is needed to improve our understanding of adult regression syndrome.
https://link.springer.com/chapter/10.1007/978-3-319-90083-4_7
“Down Syndrome Regression Disorder: Evidence of Neuroinflammations and Immunotherapy Responsiveness”
Presented by: Jonathan D. Santoro, MD
Medical Director, Neuroimmunology and Demyelinating Disorders Program
Children’s Hospital Los Angeles
https://vimeo.com/showcase/2238536/video/692902779
Password: CHRCO
Where do I go from here?
Of course, many other medical and psychiatric conditions should be ruled in or out as part of the evaluation. The differential diagnosis for a developmental regression is broad an d includes:
Catatonia
Mental health diagnoses: depression, schizophrenia, anxiety disorder
Tourette's/ tic disorder
Wilson’s Disease
Medication side effects
Hydrocephalus
Stroke(s)
Infections – encephalitis, hepatitis
Endocrine conditions like hypothyroidism, celiac disease
Autoimmune diseases & autoimmune encephalopathies (Autoimmune encephalitis, Graves’ disease, other)
More rare conditions such as
Intermediary metabolism disorders – MMA - Methylmalonic aciduria and homocystinuria, cblC type,
Homocystinuria, glutaric aciduria, carnitine metabolism disorder
Dopamine metabolism disorder – low HVA and 5HIAA metabolites in CSF
Folate receptor Alpha Defect -causes cerebral folate transport deficiency with disturbed myelin metabolism. Should show up with hypomyelination on MRI
Because this entity is poorly understood, the Down Syndrome Medical Interest Group (an international organization that meets yearly) has been working on developing standard protocols for work up and treatment.
There are many studies that can be considered in the evaluation of an individual who has regressed. Many start with basic labs, which can provide a lot of information and rule in/out a lot of more common medical conditions. Laboratory evaluation of more rare conditions should be considered based on the individual characteristics of the case
An MRI (magnetic resonance imaging) of the brain with and without contrast, as well as an EEG (electroencephalogram) are minimum studies that should be obtain to evaluate for encephalitis, seizure disorder, strokes, etc. An LP is generally recommended, as mounting evidence suggest that a sub-section of these patients have a neuroinflammatory condition that may respond to steroids and IVIG. A polysomnographic sleep study should also be part of the basic work up, as studies have shown that sleep apnea can worsen regression symptoms.
Basic Bloodwork Studies:
Complete metabolic panel
Complete blood count with differential
Vitamin D level
Hemoglobin A1c - done and normal
Urinalysis
Thyroid function: Thyroid Stimulating Hormone, Free T4 ,
Thyroid antiborides: Thyroglobulin Ab and Thyroid (TPO) Peroxidase Ab
Iron studies
Erythrocyte sedimentation rate
C-reactive protein (CRP)
Creatine Kinase
B12 level
Folate level
Ceruloplasmin and Copper level
Serum homocystine, total
Celiac serology
ANA - note this is positive in some individuals with Down syndrome without lupus. Therefore, if positive, please obtain the followign labs
Anti-cardiolipin antibodies IgG, M & A
Lupus Anti Sta Clot
DNase B Ab
Anti-cardiolipin antibodies IgG, M & A
Streptolysin O Ab (ASO)
note, if symptoms are primarily motor tics and obsessive behavior that are suggestive of a PANS diagnosis, consider sending a Cunningham panel: titers against D1 and D2 Dopamine and Tubulin. CaM Kinase II looks at activation of that enzyme by the patient’s serum to gauge level of autoimmune response. All of these measure autoimmunity.
Additional testing that can be considered:
Carnitine panel (i.e. an acylcarnitine profile plus free and total carnitine)
RPR (ruling out tertiary syphilis)
Methylmalonic acid, serum quantitative urine organic acids
Autoimmune encephalitides can cause behavioral changes, though usually it leads to abnormalities in the EEG. A variety of tests can be considered, including:
Serum Paraneoplastic autoantibody evaluation, serum panel
IgG NMDAR antibodies – neuro–autoimmune disease arising from production of aby targeting synaptic proteins. Can be paraneoplastic or not. Detected better in CSF
GAD (Glutamic Acid decarboxylase Ab)
Voltage-Gated Potassium Channel (VGKC)
AMPAR
GABA –B receptor, etc
Consider Mayo panel (profile tests + reflex tests)
There is mounting evidence that some patients with Down syndrome presenting with regression have a treatable neuro-inflammatory condition. to properly rule this out, a lumbar puncture should be performed and the following studies should be sent:
Basic studies
Routine CSF measures: opening pressure, cell counts, glucose, pH, lactate, protein
Serum & CSF IgG (IgG quotient)
Serum & CSF albumin (albumin quotient). These are now ordered as Mayo Multiple Sclerosis Panel
Oligo bands (CSF & serum)
CSF studies for neurologic disorders that can cause similar symptoms
Medical Neural Genetics (MNG) lab in Atlanta – get their forms and tubes.
Neurotransmitter levels from CSF - (5-hydroxyindoleacetic acid, homovanillic acid, 3-0-methyldopa)
To test for a Dopamine metabolism disorder – low HVA and 5HIAA metabolites in CSF
CSF Methyltetrahydrofolate to test for Folate receptor Alpha Defect that causes cerebral folate transport deficiency with disturbed myelin metabolism. Should show up with hypomyelination on MRI
Neopterin (HPLC Fluorescence) –indicator of CNS immune activation
Mayo now packages this as their CSF Neurotransmitter Profile III
Paraneoplastic autoantibody panel CSF, IgG ab – Mayo (profile tests + reflex tests).
IgG NMDAR antibodies – neuro –autoimmune disease arising from production of antibodies targeting synaptic proteins. Can be paraneoplastic or not.
GAD (Glutamic Acid decarboxylase Ab)
Voltage-Gated Potassium Channel (VGKC) = pmol/liter (nl = 0-31) (better detected in serum)
AMPAR
GABA –A receptor
Treatment of Down syndrome Regression/ Down syndrome disintegrative disorder
Treatment of regression in Down syndrome should be initiated as soon as possible, as delays in treatment are associated with worse outcomes.
Available treatment options:
Lorazepam – GABA agonist; increase by 2 mg every 3-5 days up to 16 mg. Consider a lorazepam challenge - 1.5-2 mg IV lorazepam test in clinic.Parents to take notes on behavior over next 24 hours.
ECT– GABA agonist; requires series of closely spaced treatments, often needs repeat series and/or maintenance. This has also been found to be effective
Other:
? Menentine – NMDA glutamate antagonist (down regulate NMDA receptor)
? Nuedexta 20/10. A glutamate antagonist. Start 1 capsule in the morning; increase to bid in a week if tolerated.
? N-acetylcysteine (NAC) – multiple effects (reverses ? glutamate, ?oxidative stress, antiinflammatory)
? Parkinson drugs: L-dopa (Sinemet), Anticholinergic drugs.
? Minocycline – crosses blood brain barrier, anti-inflammatory, may act as NMDA receptor antagonist; 100mg po BID with careful times regarding meals and drinking and staying upright to obviate reflux and GI distress.
In general, neuroleptics are avoided
Get Support
There is a Facebook group that connects families of individuals suffering from Down syndrome regression, also known as Down syndrome disintegrative disorder.
Research Articles on Regression
Purpose
An entity of regression in Down syndrome (DS) exists that affects adolescents and young adults and differs from autism spectrum disorder and Alzheimer disease.
Methods
Since 2017, an international consortium of DS clinics assembled a database of patients with unexplained regression and age- and sex-matched controls. Standardized data on clinical symptoms and tiered medical evaluations were collected. Elements of the proposed definition of unexplained regression in DS were analyzed by paired comparisons between regression cases and matched controls.
Results
We identified 35 patients with DS and unexplained regression, with a mean age at regression of 17.5 years. Diagnostic features differed substantially between regression cases and matched controls (p < 0.001 for all but externalizing behaviors). Patients with regression had four times as many mental health concerns (p < 0.001), six times as many stressors (p < 0.001), and seven times as many depressive symptoms (p < 0.001). Tiered medical evaluation most often identified abnormalities in vitamin D 25-OH levels, polysomnograms, thyroid peroxidase antibodies, and celiac screens. Analysis of the subset of patients with nondiagnostic medical evaluations reinforced the proposed definition.
Conclusions
Our case–control evidence supports a proposed definition of unexplained regression in Down syndrome. Establishing this clinical definition supports future research and investigation of an underlying mechanism.
Abstract: Adolescents and young adults with Down syndrome (DS) can present a rapid regression with loss of independence and daily skills. Causes of regression are unknown and treatment is most of the time symptomatic. We did a retrospective cohort study of regression cases: patients were born between 1959 and 2000, and were followed from 1984 to now. We found 30 DS patients aged 11 to 30 years old with history of regression. Regression occurred regardless of the cognitive level (severe, moderate, or mild intellectual disability (ID)). Patients presented psychiatric symptoms (catatonia, depression, delusions, stereotypies, etc.), partial or total loss of independence in activities of daily living (dressing, toilet, meals, and continence), language impairment (silence, whispered voice, etc.), and loss of academic skills. All patients experienced severe emotional stress prior to regression, which may be considered the trigger. Partial or total recovery was observed for about 50% of them. In our cohort, girls were more frequently affected than boys (64%). Neurobiological hypotheses are discussed as well as preventative and therapeutic approaches.
Objective: The main aim of this case series report is to alert physicians to the occurrence of catatonia in Down syndrome (DS). A second aim is to stimulate the study of regression in DS and of catatonia. A subset of individuals with DS is noted to experience unexplained regression in behavior, mood, activities of daily living, motor activities, and intellectual functioning during adolescence or young adulthood. Depression, early onset Alzheimer’s, or just “the Down syndrome” are often blamed after general medical causes have been ruled out. Clinicians are generally unaware that catatonia, which can cause these symptoms, may occur in DS.
Study design: Four DS adolescents who experienced regression are reported. Laboratory tests intended to rule out causes of motor and cognitive regression were within normal limits. Based on the presence of multiple motor disturbances (slowing and/or increased motor activity, grimacing, posturing), the individuals were diagnosed with unspecified catatonia and treated with anti-catatonic treatments (benzodiazepines and electroconvulsive therapy [ECT]).
Results: All four cases were treated with a benzodiazepine combined with ECT and recovered their baseline functioning.
Conclusion: We suspect catatonia is a common cause of unexplained deterioration in adolescents and young adults with DS. Moreover, pediatricians and others who care for individuals with DS are generally unfamiliar with the catatonia diagnosis outside schizophrenia, resulting in misdiagnosis and years of morbidity. Alerting physicians to catatonia in DS is essential to prompt diagnosis, appropriate treatment, and identification of the frequency and course of this disorder.